Financial Review: Surrozen (NASDAQ:SRZN) & SAB Biotherapeutics (NASDAQ:SABS)

Surrozen (NASDAQ:SRZN – Get Rating) and SAB Biotherapeutics (NASDAQ:SABS – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk.

Valuation and Earnings

This table compares Surrozen and SAB Biotherapeutics’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$12.50 million	1.47	-$36.00 million	($1.29)	-0.47
SAB Biotherapeutics	$23.90 million	1.87	-$18.74 million	N/A	N/A

SAB Biotherapeutics has higher revenue and earnings than Surrozen.

Profitability

This table compares Surrozen and SAB Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Surrozen	N/A	-54.93%	-46.83%
SAB Biotherapeutics	-213.54%	-87.92%	-52.78%

Risk and Volatility

Surrozen has a beta of -0.33, meaning that its share price is 133% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.

Insider and Institutional Ownership

62.1% of Surrozen shares are held by institutional investors. Comparatively, 20.9% of SAB Biotherapeutics shares are held by institutional investors. 35.4% of Surrozen shares are held by company insiders. Comparatively, 42.0% of SAB Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Surrozen and SAB Biotherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	2	1	0	0	1.33
SAB Biotherapeutics	0	0	2	0	3.00

SAB Biotherapeutics has a consensus price target of $3.67, indicating a potential upside of 313.24%. Given SAB Biotherapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than Surrozen.

Summary

SAB Biotherapeutics beats Surrozen on 8 of the 12 factors compared between the two stocks.

About Surrozen

(Get Rating)

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

About SAB Biotherapeutics

(Get Rating)

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.